ArticleNature2025
Imidazole propionate is a driver and therapeutic target in atherosclerosis.
Registry-linked trialAbstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06935279 (Bacteria in Atherosclerotic Plaques and Adverse Events), which is not on this map. Cited by 59 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bacteria in Atherosclerotic Plaques and Adverse Events
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gut Microbiota and Its Metabolites in the Prognosis of Coronary Heart Disease: A Systematic Review and Mechanistic Insights.Cardiovascular drugs and therapy · 2026Pooled it
- Heart-Gut Axis in Cardiometabolic Disease: Microbiome-Mediated Pathways Linking Metabolic Syndrome to Cardiovascular Risk.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Effect of a polyphenol-rich pomegranate extract on plasma trimethylamine N-oxide levels following an oral carnitine challenge: a randomized controlled crossover trial in healthy adults.Frontiers in nutrition · 2026Trial
- Microbial metabolite-driven mechanisms linking the gut microbiome to atherosclerosis: multi-omic and translational perspectives.Gut microbes · 2026Review
- Cardiovascular-kidney-metabolic syndrome through the lens of gut‑derived uremic toxins.Gut microbes · 2026Review
- An oral-gut microbial metabolite linksGut microbes · 2026Article
- Gut microbiota and immunometabolism in obesity.Gut microbes · 2026Review
- Histidine-improved cancer immunosurveillance.Oncoimmunology · 2026Article
- Review
- Gut microecology and cardiovascular disease: core pathogenic mechanisms and clinical intervention strategies.Folia microbiologica · 2026Review
- Gut microbiota-derived imidazole propionate promotes primary sclerosing cholangitis via p38 signalling.Nature metabolism · 2026Article
- Anaerobic riboflavin degradation by human gutJournal of bacteriology · 2026Article
- Gut microbial metabolites and cardiometabolic disorders: new targets for prevention and treatment.European heart journal · 2026Article
- Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.European heart journal · 2026Article
- Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.Nature medicine · 2026Article
- Eggerthella lenta: metabolism, pathogenesis and therapeutic implications.Nature reviews. Microbiology · 2026Review
- Urinary carnosine links diet quality with one-carbon and lipid metabolism: insights from an interpretive framework for imidazole metabolites.European journal of nutrition · 2026Article
- The microbiome regulates host metabolic health and diseases through microbial enzymes.Nature reviews. Gastroenterology & hepatology · 2026Review
- Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology.Nature communications · 2026Article
- Microbiome histidine competition mediates dietary control of systemic imidazole propionate.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Annalaura Mastrangelo *Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0003-2650-0444
Iñaki Robles-Vera *Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0001-6002-9241
Diego MañanesCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0001-7247-6794
Miguel GalánCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0002-6695-1509
Marcos Femenía-MuiñaCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Ana Redondo-UrzainquiCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Rafael Barrero-RodríguezCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Eleftheria PapaioannouInstitute for Biomedical Research Sols-Morreale (IIBM), Spanish National Research Council-Universidad Autónoma de Madrid, Madrid, Spain.
Joaquín Amores-IniestaCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Ana DevesaCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0001-5981-2546
Manuel Lobo-GonzálezCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Alba CarrerasThe Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Katharina R BeckThe Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Sophie IvarssonThe Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0009-0009-4050-9075
Anders GummessonThe Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Georgios GeorgiopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Manuel Rodrigo-TapiasCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Sarai Martínez-CanoCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Ivan Fernández-LópezCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Vanessa NuñezCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Alessia FerrariniCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0002-4587-6095
Naohiro InoharaDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Kimon StamatelopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Alberto BenguríaCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0002-5536-566X
Danay CibrianCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Francisco Sánchez-MadridCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Vanesa Alonso-HerranzCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, Boadilla del Monte, Spain.
Ana DopazoCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0002-4910-1684
Coral BarbasCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, Boadilla del Monte, Spain.ORCID 0000-0003-4722-491X
Jesús VázquezCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0003-1461-5092
Juan Antonio LópezCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0002-9097-6060
Alicia González-MartínInstitute for Biomedical Research Sols-Morreale (IIBM), Spanish National Research Council-Universidad Autónoma de Madrid, Madrid, Spain.
Gabriel NuñezDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Konstantinos StellosDepartment of Cardiovascular Research, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0000-0002-0194-0825
Göran BergströmThe Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-4289-5722
Fredrik BäckhedThe Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Valentín FusterCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Borja IbañezCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.ORCID 0000-0002-5036-254X
David SanchoCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain. dsancho@cnic.es.ORCID 0000-0003-2890-3984
Funding
National Metabolomics Data Repository - nextgen Metabolomics WorkbenchU2CDK119886 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2018 to 2021
$12.7MBiomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2020 to 2024
$3.2MNIDDK NIH HHS U2C DK119886NIH HHS OT2 OD030544
Abstract
Atherosclerosis is the main underlying cause of cardiovascular diseases. Its prevention is based on the detection and treatment of traditional cardiovascular risk factors
Indexed as
AtherosclerosisImidazolesMolecular Targeted TherapyPropionatesAnimalsCohort StudiesDiet, High-FatDisease ProgressionFemaleHumansInflammationMaleMiceMice, Inbred C57BLImidazolesPropionates
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT06935279ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.